Manuel Alba, serving as a director at Astera Labs, Inc. (NASDAQ: ALAB), completed the sale of 129,916 common shares on July 1, 2026. The transaction resulted in proceeds of approximately $60.5 million. The execution of these sales took place at prices ranging from $429.578 to $459.0178, levels that align closely with the stock's prevailing market price of $432.74.
The timing of this divestment follows a substantial 383% increase in the stock's value over the preceding twelve months. Despite this upward trajectory, analytical assessments indicate that the equity may be trading above its intrinsic worth. Specifically, the stock is positioned among the most overvalued securities in the current market relative to its calculated Fair Value.
The shares were liquidated automatically under the parameters of a Rule 10b5-1 trading plan. This plan was originally established by Mr. Alba on May 29, 2025. The securities involved are held indirectly through the Alba 2003 Living Trust, for which Mr. Alba and his spouse serve as co-trustees. Mr. Alba has formally disclaimed beneficial ownership of these securities, except insofar as his pecuniary interest is concerned.
Post-transaction, Mr. Alba's indirect ownership of Astera Labs common stock via the Alba Trust stands at 1,287,524 shares. This activity occurs against a backdrop of mixed analyst sentiment regarding the semiconductor connectivity firm. UBS recently adjusted its financial estimates for both Marvell Technology and Astera Labs, emphasizing the expanding potential within the Compute Express Link (CXL) technology sector. UBS retained a Buy rating for Marvell and a Neutral rating for Astera Labs, while raising price targets to $340 and $400, respectively.
Conversely, Northland initiated a downgrade for Astera Labs to a Market Perform rating. This decision was driven by valuation concerns, alongside apprehensions over potential supply chain disruptions and a decline in AI infrastructure spending. Consequently, Northland removed its previous price target of $225. This downgrade aligns with broader sector-wide adjustments affecting several semiconductor stocks.
Corporate governance developments also proceeded during this period. Astera Labs convened its 2026 Annual Stockholders Meeting, where shareholders elected three Class II directors to the board. The newly appointed directors, Sanjay Gajendra, Craig Barratt, and Michael Hurlston, are scheduled to serve until the 2029 annual meeting.
Stifel maintained its Buy rating on Astera Labs with a price target of $260 following investor engagements at its Cross-Sector 1-on-1 2026 conference. The juxtaposition of these analyst actions highlights a complex environment where technological growth opportunities clash with valuation scrutiny and macroeconomic headwinds in the AI infrastructure space.